Curewell Capital Acquires Majority Stake in Wilmington PharmaTech

Wilmington PharmaTech (WPT), a manufacturer of small molecule active pharmaceutical ingredients (API) based in the United States, has entered into a significant partnership with Curewell Capital, a private equity firm located in Los Angeles. The deal involves Curewell acquiring a majority investment in WPT, aimed at accelerating the company’s growth and enhancing its manufacturing capabilities within the domestic pharmaceutical sector.

Wilmington PharmaTech has been a key player in the pharmaceutical manufacturing landscape since its establishment in 2003. The company specializes in providing integrated services that encompass drug discovery, clinical development, and commercial-scale manufacturing. Its facilities, located on a 54-acre campus in Delaware, include two state-of-the-art production sites equipped with current Good Manufacturing Practices (cGMP) and high potency API suites, as well as an R&D center in Suzhou, China.

Hui-Yin “Harry” Li, Ph.D., the founder and CEO of Wilmington PharmaTech, will retain a substantial ownership stake in the company and continue to lead it alongside the existing management team. Dr. Li expressed optimism about the partnership, stating, “Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies.” He emphasized the company’s commitment to expanding its capabilities and capacity to better serve global biopharmaceutical partners.

The investment from Curewell Capital is positioned to provide substantial growth capital, which will enable Wilmington PharmaTech to expand its manufacturing footprint significantly. Michael Dal Bello, a partner at Curewell Capital, highlighted the importance of this investment, noting the increasing demand for specialized pharmaceutical manufacturing in the United States. “Our investment will help WPT accelerate its next phase of growth amid strong market demand for dependable, high-quality capacity,” said Dal Bello.

This transaction not only empowers Wilmington PharmaTech to enhance its operational capabilities but also positions the company to capitalize on the growing domestic and international demand for advanced API development. The partnership is expected to solidify WPT’s role as a critical U.S. manufacturing partner for biopharma innovators, contributing to the strengthening of domestic pharmaceutical manufacturing.

As the pharmaceutical industry continues to evolve, the collaboration between Wilmington PharmaTech and Curewell Capital stands as a testament to the growing emphasis on quality and reliability in drug development and manufacturing processes. This investment reflects a broader trend within the industry to bolster domestic capacities and cater to the increasing needs of global drug developers.